97 related articles for article (PubMed ID: 10532108)
1. [Administration of liposomal preparation of DaunoXome for breast cancer in patients with poor prognosis].
Darskaia EI; Zubarovskaia LS; Afanas'ev BV
Vopr Onkol; 1999; 45(4):440-4. PubMed ID: 10532108
[TBL] [Abstract][Full Text] [Related]
2. Safety and early efficacy assessment of liposomal daunorubicin (DaunoXome) in adults with refractory or relapsed acute myeloblastic leukaemia: a phase I-II study.
Fassas A; Buffels R; Anagnostopoulos A; Gacos E; Vadikolia C; Haloudis P; Kaloyannidis P
Br J Haematol; 2002 Feb; 116(2):308-15. PubMed ID: 11841431
[TBL] [Abstract][Full Text] [Related]
3. Liposomal daunorubicin (DaunoXome) for treatment of poor-risk acute leukemia.
Russo D; Piccaluga PP; Michieli M; Michelutti T; Visani G; Gugliotta L; Bonini A; Pierri I; Gobbi M; Tiribelli M; Fanin R; Piccolrovazzi S; Baccarani M
Ann Hematol; 2002 Aug; 81(8):462-6. PubMed ID: 12224004
[TBL] [Abstract][Full Text] [Related]
4. [The therapeutic efficacy and toxicity of the liposomal form of daunorubicin (Daunoxome) in lymphosarcoma patients].
Medvedev PV; Nikitin EA; Pivnik AV
Ter Arkh; 2000; 72(7):38-42. PubMed ID: 10983319
[TBL] [Abstract][Full Text] [Related]
5. Kaposi's sarcoma: DaunoXome approved.
AIDS Treat News; 1996 May; (no 246):3-4. PubMed ID: 11363485
[TBL] [Abstract][Full Text] [Related]
6. Extravasation of liposomal daunorubicin in patients with AIDS-associated Kaposi's sarcoma: a report of four cases.
Cabriales S; Bresnahan J; Testa D; Espina BM; Scadden DT; Ross M; Gill PS
Oncol Nurs Forum; 1998; 25(1):67-70. PubMed ID: 9460774
[TBL] [Abstract][Full Text] [Related]
7. Phase I clinical trial of liposomal daunorubicin in hepatocellular carcinoma complicating liver cirrhosis.
Daniele B; De Vivo R; Perrone F; Lastoria S; Tambaro R; Izzo F; Fiore F; Vallone P; Pignata S
Anticancer Res; 2000; 20(2B):1249-51. PubMed ID: 10810429
[TBL] [Abstract][Full Text] [Related]
8. DaunoXome shows promise as breast cancer treatment.
Oncology (Williston Park); 1996 Mar; 10(3):425. PubMed ID: 8820459
[No Abstract] [Full Text] [Related]
9. A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancer.
O'Byrne KJ; Thomas AL; Sharma RA; DeCatris M; Shields F; Beare S; Steward WP
Br J Cancer; 2002 Jul; 87(1):15-20. PubMed ID: 12085249
[TBL] [Abstract][Full Text] [Related]
10. Liposomal daunorubicin: new preparation. Kaposi's sarcoma: occasional remission.
Prescrire Int; 1998 Apr; 7(34):41-2. PubMed ID: 10183380
[TBL] [Abstract][Full Text] [Related]
11. Non-pegylated liposomal doxorubicin in metastatic breast cancer patients: a valuable therapeutic option requiring caution.
Bernardi D; Errante D; Stefani M; Salvagno L
Breast; 2010 Dec; 19(6):549-50. PubMed ID: 20542696
[No Abstract] [Full Text] [Related]
12. Liposomal daunorubicin (DaunoXome) for treatment of relapsed meningeal acute myeloid leukemia.
Piccaluga PP; Visani G; Martinelli G; Isidori A; Malagola M; Rondoni M; Baccarani M; Tura S
Leukemia; 2002 Sep; 16(9):1880-1. PubMed ID: 12200714
[No Abstract] [Full Text] [Related]
13. Phase II studies with DaunoXome in patients with nonresectable hepatocellular carcinoma: clinical and pharmacokinetic outcomes.
Yeo W; Chan KK; Mukwaya G; Ross M; Leung WT; Ho S; Chan AT; Johnson PJ
Cancer Chemother Pharmacol; 1999; 44(2):124-30. PubMed ID: 10412946
[TBL] [Abstract][Full Text] [Related]
14. [Results of a phase I-II clinical trial of Emoxyl, a novel antineoplastic anthracycline].
Korman DB; Mikaélian SG; Boronovskaia LE; Maslova IA
Vopr Onkol; 2004; 50(2):202-7. PubMed ID: 15176224
[TBL] [Abstract][Full Text] [Related]
15. NeXstar Pharmaceuticals lauches DaunoXome.
J Int Assoc Physicians AIDS Care; 1996 Jun; 2(6):52. PubMed ID: 11363700
[TBL] [Abstract][Full Text] [Related]
16. A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993).
Coleman RE; Biganzoli L; Canney P; Dirix L; Mauriac L; Chollet P; Batter V; Ngalula-Kabanga E; Dittrich C; Piccart M
Eur J Cancer; 2006 May; 42(7):882-7. PubMed ID: 16520033
[TBL] [Abstract][Full Text] [Related]
17. Liposomal anthracyclines for breast cancer.
Sparano JA; Winer EP
Semin Oncol; 2001 Aug; 28(4 Suppl 12):32-40. PubMed ID: 11552228
[TBL] [Abstract][Full Text] [Related]
18. Higher plasma but not intracellular concentrations after infusion with liposomal daunorubicin compared with conventional daunorubicin in adult acute myeloid leukemia.
Löfgren C; Lehmann S; Jönsson-Videsäter K; Möllgård L; Linder O; Tidefelt U; Hassan M; Paul C
Ther Drug Monit; 2007 Oct; 29(5):626-31. PubMed ID: 17898654
[TBL] [Abstract][Full Text] [Related]
19. Liposomal daunorubicin is not recommended in patients with less than advanced HIV-related Kaposi's sarcoma.
White RM
AIDS; 1997 Sep; 11(11):1412-3. PubMed ID: 9302461
[No Abstract] [Full Text] [Related]
20. Phase I study of liposomal daunorubicin in relapsed and refractory acute myeloid leukemia.
Bieker R; Lerchenmüller C; Wehmeyer J; Serve HL; Mesters RM; Büchner T; Berdel WE
Oncol Rep; 2003; 10(4):915-20. PubMed ID: 12792745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]